UBS Group
MATN

UBS Group’s Mateon Therapeutics, Inc. MATN Stock Holding History

UBS Group’s Portfolio MATN Stock Details MATN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,188
Closed -$1K – 8360
2016
Q3 		$1K Sell
1,188
-7,965
-87% -$5.39K ﹤0.01% 7594
2016
Q2 		$6K Buy
+9,153
New +$6.48K ﹤0.01% 7085

Other funds holding MATN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

UBS Group's MATN Position: Q4 2016 in Review

UBS Group sold out of Mateon Therapeutics, Inc. (MATN) in Q4 2016, closing a stake of 1,188 shares — an estimated $1K sold.

UBS Group first reported a position in MATN in Q2 2016 and held it in 2 quarters. The position peaked at $6K in Q2 2016. 1 fund tracked by Wall St. Rank holds MATN as of Q4 2016.

  • UBS Group reported no remaining Mateon Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • UBS Group sold 1,188 Mateon Therapeutics, Inc. shares in Q4 2016, an estimated $1K.
  • UBS Group first reported a position in Mateon Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • UBS Group's Mateon Therapeutics, Inc. position peaked at $6K in Q2 2016.
  • 1 fund tracked by Wall St. Rank held Mateon Therapeutics, Inc. as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.